Filing Details
- Accession Number:
- 0001209191-14-048230
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-07-21 18:40:10
- Reporting Period:
- 2014-07-17
- Filing Date:
- 2014-07-21
- Accepted Time:
- 2014-07-21 18:40:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1365216 | Sucampo Pharmaceuticals Inc. | SCMP | Pharmaceutical Preparations (2834) | 133929237 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1384384 | S&R Technology Holdings, Llc | 7501 Wisconsin Avenue Suite 600E Bethesda MD 20814-6519 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Disposition | 2014-07-17 | 7,600 | $6.27 | 22,813,202 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2014-07-18 | 7,400 | $6.27 | 22,805,802 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2013.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.34, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.35, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.